Zacks Investment Research on MSN
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
Ionis Pharmaceuticals IONS reported third-quarter 2025 adjusted loss per share of 61 cents, much narrower than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback